XBiotech Inc

Day range

$1.95 – $1.99

Open

$1.95

Prev close

$1.96

Volume

105.43K

Market cap

$59.76M

Shares out

30.49M

P/E

—

P/S

—

P/B

0.47

P/FCF

—

ROE

-35.1%

ROA

-33.8%

Debt/Equity

0.00

Div yield

0.00%

As of Nov 13, 2026

• Ceo appointmentOct 26, 2026

  XBiotech announces that the Board of Directors has appointed Dr. Sushma Shivaswamy and Jan-Paul Simard to serve as Co-Chief Executive Officers of the Company effective October 23, 2026.

• Ceo appointmentDec 9, 2025

  Sushma Shivaswamy, 47, who has served as XBiotech's Chief Scientific Officer since November 2017, has been appointed to serve as the Company's interim CEO effective December 8, 2025. Her annual base salary will be increased to $750,000 while she serves in these roles, with a bonus structure and a full remuneration package to be determined by the Compensation Committee at a later time.

• Executive compensation changeOct 3, 2025

  On October 2, 2025, John Simard and XBiotech, Inc. (the "Company") entered into an Executive Employment Agreement (the "Agreement"), with an effective date of October 1, 2025, to replace and supersede all prior employment agreements between Mr. Simard and the Company. Under the Agreement, Mr. Simard will maintain his current annual Base Salary of USD $1,250,000. Mr. Simard will also be eligible to receive an annual Base Bonus of USD $4,530,442.00, which reflects the average annual bonus paid over the past 5 years.

• Annual meeting resultsSep 2, 2025

  The annual meeting of the stockholders of XBiotech Inc. (the "Company") was held on August 29, 2025. The matters that were voted upon at the meeting, and the number of votes cast for and against, as well as the number of abstentions and broker non-votes as to each such matter, are set forth below. Stockholders voted in accordance with the Board of Directors' recommendations on each matter and voted to (1) elect five nominees for director; (2) ratify the selection by the Audit Committee of the Board of Directors of Whitley Penn LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025; (3) approve, on an advisory basis, the compensation of the Company's named executive officers; (4) approve the Company's 2025 Equity Incentive Plan.

• Director appointmentJun 24, 2025

  XBiotech Inc. announces the June 24, 2025 appointments of Dr. Thomas Kündig and Craig Rademaker to the Company's Board of Directors. Dr. Kündig has further been appointed to serve on the Compensation Committee, while Mr. Rademaker has been appointed to serve on the Audit Committee.

Days to cover

2.6

Short interest

315.31K

Avg volume

119.22K

As of Oct 30, 2026 · reported to FINRA twice monthly.

• XBiotech annonce la nomination de Sushma Shivaswamy et Jan-Paul Simard aux postes de co-directeurs généraux
  positiveGlobeNewswire Inc.· Oct 24, 2026
• XBiotech gibt die Wahl von Sushma Shivaswamy und Jan-Paul Simard zu Co-Chief Executive Officers bekannt
  positiveGlobeNewswire Inc.· Oct 24, 2026
• XBiotech annonce des résultats d’efficacité finaux positifs de phase II pour l’essai TASKIN commandité par un chercheur dans le cancer colorectal métastatique réfractaire
  positiveGlobeNewswire Inc.· Oct 19, 2026
• XBiotech gibt positive endgültige Wirksamkeitsergebnisse der Phase-II-Studie „TASKIN“ bekannt, einer von Forschern initiierten Studie zur Behandlung von refraktärem metastasiertem Kolorektalkarzinom
  positiveGlobeNewswire Inc.· Oct 19, 2026
• XBiotech Announces Positive Phase II Final Efficacy Results from Investigator-Sponsored TASKIN Trial in Refractory Metastatic Colorectal Cancer
  positiveGlobeNewswire Inc.· Oct 19, 2026